About FastBiotic™

 

FastBiotic™ is a dietary supplement designed to support the immune system by a well-tasting on-the-go solution for both children and adults. FastBiotic™ contains two well-documented probiotic strains within immune health:

•    L. rhamnosus GG
•    B. lactis BL-04

FastBiotic™ is powder in a stick designed for dosing directly on the tongue without the need for water. FastBiotic™ is manufactured in cGMP FDA Approved Facility.


> ORDER NOW

Microbes & the immune system
The human microbiota plays a crucial role in achieving a well-functioning immune system. By primarily interacting with the part of immune system associated with the digestive tract, comprising 70 % of the immune system, the microbiota is able to modulate and balance the immune system (Purchiaroni 2013). Probiotics work in a similar fashion by modulating the local and systemic immune system and thereby supporting the function of the immune system (Kemgang 2014; Hevia 2015).

Strengthening the immune system
Today, acute respiratory tract infections (ARTIs), such as upper respiratory tract infections and common colds, are still highly prevalent especially in children, accounting for approximately 70 % of the primary diagnosis at care office visits. Antibiotics are often prescribed for ARTIs with limited effect, which makes different approaches to support the immune system before and during ARTIs much needed (McDonagh 2016; Zeng 2014).

The consumption of probiotics presents an alternative approach to strengthen the immune system, since probiotics have been shown to both reduce the incidence and duration of acute upper respiratory tract infections (URTIs), as well as reducing antibiotic prescription and absence from school or daycare (Araujo 2015; Hao 2015; King 2014).

The mode of action is colonization in the intestines. From here the probiotics promote health benefits by improving mucosal barrier function and immunomodulating activity (Bermudez-Brito 2012).

FastBiotic™

FastBiotic™ contains two well-studied probiotic strains:

• Lactobacillus rhamnosus GG
• Bifidobacterium lactis BL-04

By combining these particular species, FastBiotic™ covers the entire intestines, since lactobacilli and bifidobacteria are primarily found in the upper and lower intestines, respectively.

L. rhamnosus GG has been shown to be effective in decreasing the number, severity and duration of respiratory tract infections in children in several clinical studies (Liu 2013). In one of those studies, children consuming L. rhamnosus GG had a significantly reduced risk of upper respiratory tract infections, significantly fewer days with respiratory symptoms, and on average 2 days less absence from day care due to infections (Hojsak 2010a).


These results support findings in a study from 2001, which included 571 healthy children from day care centers in Finland. Children supplemented with L. rhamnosus GG had fewer days of absence from day care due to illness, reduced risk of respiratory tract infections, and decreased use of antibiotics for treating respiratory infections compared with placebo, which is backed up by investigations from a recent study (Hatakka 2001; Kumpu 2013).

L. rhamnosus GG is also effective in reducing the risk of both gastrointestinal and respiratory infections in hospitalized children. This was shown in a study from 2010 with 742 children enrolled (Hojsak 2010b).



B. lactis BL-04 has shown beneficial effects in a 5- months long clinical study. The participants who received B. lactis BL-04 had a 27% reduced risk of upper respiratory tract infections (URTIs) compared to placebo. In addition, the time to first URTI was delayed – extending the period before experiencing an infection (West 2014).

Additionally, the reduced risk of 27 % of URTIs could also be seen from the lower numbers of episodes in the probiotic group (fig. 4).


How and when to use FastBiotic™
FastBiotic™ is suitable for toddlers, children and adults to use on a daily basis as a year-round support for general immunity and especially during the cold/flu season.

The single dosed stick solution is easy to bring on-the-go.
You can bring just the sticks you need during a trip, and they can easily fit into a small briefcase or the pocket of your jacket. Recommended dosage is 1 stick per day. The stick opens easily with a snap at the laser made precut. Pour the powder directly into your mouth. The powder dissolves instantly - no need for water.

Stability
Based on extensive expertise within probiotic strain selection, product formulation and manufacturing, FastBiotic™ has been designed to have a shelf life of 24 months when stored at ambient temperature.


The expected course of the FastBiotic™ stability is based on technological experience. Further, the course of the FastBiotic™ is corroborated by data from several development batches showing similar stability.

The cell count at end-of-shelf-life corresponds to the dosage used in the human clinical studies:

• 1 billion CFU of L. rhamnosus GG
• 2 billion CFU of B. lactis BL-04

> ORDER NOW


REFERENCES:


Bermudez-Brito M, Plaza-Diáz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab 2012; 61: 160 -174

Chambial S, Dwivedi S, Shukla KK, John PJ, Sharma P. Vitamin C in disease prevention and cure: An overview. Ind J Clin Biochem 2013;28(4): 314-328.

de Araujo GV, de Oliveira Junior MH, Peixoto DM, Sarinho ESC. Probiotics for the treatment of upper and lower respiratory-tract infections in children: systematic review based on randomized clinical trials. J Pediatr (Rio J.) 2015; 91(5): 413-427.

EFSA Journal 2009;7(9):1226. Scientific opinion on the substantiation of health claims related to vitamin C and function of the immune system (health claim ID: 134).

Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database of Systematic Reviews 2015, Issue 2. Art. No.: CD006895.

Hatakka K, Savilahti E, Pönkä A, Meurman JH, Poussa T, Näse L, Saxelin M, Korpela R. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial.  BMJ. 2001; 322(7298): 1327.

Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database of Systematic Reviews 2013, Issue 1.Art. No.: CD000980.

Hevia A, Delgado S, Sánchez B, Margolles A. Molecular players involved in the interaction between beneficial bacteria and the immune system. Front Microbiol 2015; 6: article 1285.

Hojsak I, Abdović S, Szajewska H, Milosević M, Krznarić Z, Kolacek S. Lactobacillus GG in the prevention of nosocomial gastrointestinal and respiratory tract infections. Pediatrics. 2010b; 125(5): e1171-1177.

Hojsak I, Snovak N, Abdović S, Szajewska H, Misak Z, Kolacek S. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2010a; 29(3): 312-31.

Kemgang TS, Kapila S, Shanmugam VP, Kapila R. Cross-talk between probiotic lactobacilli and host immune system. J Appl Microbiol 2014; 117: 303-319.

King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Brit J Nutr 2014; 112: 41-54.

Kumpu M, Lehtoranta L, Roivainen M, Ronkko E, Ziegler T. The use of the probiotic Lactobacillus rhamnosus GG and viral findings in the nasopharynx of children attending day care. J. Med. Virol 2013; 85:1632-1638.

Liu S, Hu PW, Du X, Zhou T, Pei X. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: A meta-analysis of randomized, placebo-controlled trials. Indian Pediatr 2013; 50(4): 377-381.

McDonagh M, Peterson K, Winthrop K, Cantor A, Holzhammer B, Buckley DI. Improving antibiotic prescribing for uncomplicated acute respiratory tract infections. Agency for Healthcare Research and Quality (AHRQ) 2016; Comparative Effectiveness Review; 163: 1-138. Page 1 cited.

Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E, Gasbarrini A. The role of the intestinal microbiota and the immune system. Eur Rev Med Pharmacol Sci 2013;17(3): 323-333.

West NP, Horn PL, Pyne DB, Gebski VJ, Lahtinen SJ, Fricker PA, Cripps AW. Probiotic supplementation for respiratory and gastrointestinal illness symptoms in healthy physically active individuals. Clin Nutr 2014; 33(4): 581-587.

Zeng L, Zhang L, Hu Z, Ehle EA, Chen Y, Liu L, Chen M. Sytematic review of evidence-based guidelines on medication therapy for upper respiratory tract infection in children with AGREE instrument. PLoS ONE 2014; 9(2): e87711; pp. 1-13

 

SaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSaveSave